Publication:
Congenital myasthenic syndromes in the Thai population: Clinical findings and novel mutations

dc.contributor.authorNalinee Pattrakornkulen_US
dc.contributor.authorChupong Ittiwuten_US
dc.contributor.authorPonghatai Boonsimmaen_US
dc.contributor.authorKanokwan Boonyapisiten_US
dc.contributor.authorChaiyos Khongkhatithumen_US
dc.contributor.authorOranee Sanmaneechaien_US
dc.contributor.authorKanya Suphapeetipornen_US
dc.contributor.authorVorasuk Shotelersuken_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherKing Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn Universityen_US
dc.contributor.otherFaculty of Medicine, Ramathibodi Hospital, Mahidol Universityen_US
dc.contributor.otherFaculty of Medicine, Siriraj Hospital, Mahidol Universityen_US
dc.date.accessioned2020-11-18T10:02:39Z
dc.date.available2020-11-18T10:02:39Z
dc.date.issued2020-10-01en_US
dc.description.abstract© 2020 Elsevier B.V. Congenital myasthenic syndromes (CMS) comprise a heterogeneous group of genetic disorders of the neuromuscular junction. Next generation sequencing has been increasingly used for molecular diagnosis in CMS patients. This study aimed to identify the disease-causing variants in Thai patients. We recruited patients with a diagnosis of CMS based on clinical and electrophysiologic findings, and whole exome sequencing was performed. Thirteen patients aged from 2 to 54 years (median: 8 years) from 12 families were enrolled. Variants were identified in 9 of 13 patients (69%). Five novel variants and two previously reported variant were found in the COLQ, RAPSN and CHRND gene. The previously reported c.393+1G>A splice site variant in the COLQ gene was found in a majority of patients. Five patients harbor the homozygous splice site c.393+1G>A variant, and two patients carry compound heterozygous c.393+1G>A, c.718–1G>T, and c.393+1G>A, c.865G>T (p.Gly289Ter) variants. The novel variants were also found in RAPSN (p.Cys251del, p.Arg282Cys) and CHRND (p.Met481del). Molecular diagnosis in CMS patients can guide treatment decisions and may be life changing, especially in patients with COLQ mutations.en_US
dc.identifier.citationNeuromuscular Disorders. Vol.30, No.10 (2020), 851-858en_US
dc.identifier.doi10.1016/j.nmd.2020.08.362en_US
dc.identifier.issn18732364en_US
dc.identifier.issn09608966en_US
dc.identifier.other2-s2.0-85091535485en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/60068
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85091535485&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleCongenital myasthenic syndromes in the Thai population: Clinical findings and novel mutationsen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85091535485&origin=inwarden_US

Files

Collections